Final answer:
The iPLEDGE program requires prescribers and patients to register and meet specific requirements to prescribe and receive isotretinoin, due to its high risk of causing birth defects.
Step-by-step explanation:
The program in question that requires prescribers to be registered and activated to prescribe isotretinoin to registered patients who meet all the requirements is the iPLEDGE program. This risk management program aims to prevent fetal exposure to isotretinoin, which can cause severe birth defects. To prescribe isotretinoin, prescribers must be registered with the program, and patients receiving the prescription must comply with the comprehensive set of requirements designed to ensure that no pregnant woman takes isotretinoin and that no woman becomes pregnant while taking the drug.